IL139969A0 - A pharmaceutical formulation for insulin-like growth factor and insulin like growth factor binding protein - Google Patents

A pharmaceutical formulation for insulin-like growth factor and insulin like growth factor binding protein

Info

Publication number
IL139969A0
IL139969A0 IL13996999A IL13996999A IL139969A0 IL 139969 A0 IL139969 A0 IL 139969A0 IL 13996999 A IL13996999 A IL 13996999A IL 13996999 A IL13996999 A IL 13996999A IL 139969 A0 IL139969 A0 IL 139969A0
Authority
IL
Israel
Prior art keywords
insulin
growth factor
binding protein
pharmaceutical formulation
igfbp
Prior art date
Application number
IL13996999A
Other languages
English (en)
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Publication of IL139969A0 publication Critical patent/IL139969A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL13996999A 1998-06-01 1999-05-28 A pharmaceutical formulation for insulin-like growth factor and insulin like growth factor binding protein IL139969A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/089,062 US6436897B2 (en) 1998-06-01 1998-06-01 Pharmaceutical formulations for IGF/IGFBP
PCT/US1999/012173 WO1999062536A2 (en) 1998-06-01 1999-05-28 Pharmaceutical formulations for igf/igfbp

Publications (1)

Publication Number Publication Date
IL139969A0 true IL139969A0 (en) 2002-02-10

Family

ID=22215473

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13996999A IL139969A0 (en) 1998-06-01 1999-05-28 A pharmaceutical formulation for insulin-like growth factor and insulin like growth factor binding protein

Country Status (14)

Country Link
US (2) US6436897B2 (zh)
EP (1) EP1082133B1 (zh)
JP (1) JP2002516871A (zh)
KR (1) KR20010052500A (zh)
CN (1) CN1201816C (zh)
AT (1) ATE270898T1 (zh)
AU (1) AU4326799A (zh)
BR (1) BR9910863A (zh)
CA (1) CA2330925C (zh)
DE (1) DE69918690T2 (zh)
ES (1) ES2221456T3 (zh)
HK (1) HK1040637B (zh)
IL (1) IL139969A0 (zh)
WO (1) WO1999062536A2 (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
ES2180416B1 (es) * 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
US20100143442A1 (en) 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
AU2003900481A0 (en) 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
AU2003903896A0 (en) 2003-07-28 2003-08-07 Queensland University Of Technology Skin regeneration system
AU2005277357B2 (en) 2004-08-17 2011-08-04 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
ES2341270T3 (es) * 2004-12-24 2010-06-17 Insmed, Inc. Complejos rhigf-i/rhigfbp-3 purificados y procedimientos de fabricacion de los mismos.
CA2594580C (en) * 2005-01-25 2013-09-24 Wyeth Research Ireland Limited Method for diafiltration
CN101141975B (zh) 2005-03-25 2012-05-23 瑞泽恩制药公司 Vegf拮抗剂制剂
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
KR101406811B1 (ko) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
CN101484469B (zh) 2006-08-31 2012-12-12 弗·哈夫曼-拉罗切有限公司 生产胰岛素样生长因子-ⅰ的方法
AU2008319053B2 (en) 2007-11-01 2012-04-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
US8404639B2 (en) 2008-10-29 2013-03-26 The Rockefeller University Methods and kits for treating disease by administering insulin-like growth factor binding protein-2
EP2507261B1 (en) 2009-11-30 2016-12-21 Factor Therapeutics Limited Fibronectin: growth factor chimeras
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US20190293527A1 (en) * 2013-02-04 2019-09-26 Charm Sciences, Inc. Extraction of mycotoxins
US11035764B2 (en) * 2012-02-03 2021-06-15 Charm Sciences, Inc. Extraction of mycotoxins
KR102238677B1 (ko) 2012-09-07 2021-04-12 코히러스 바이오사이언시즈, 인코포레이티드 아달리무맙의 안정한 수성 제형
TR201909951T4 (tr) 2014-07-18 2019-07-22 Sanofi Sa Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
WO2016209773A1 (en) * 2015-06-22 2016-12-29 Dots Technology Corp. Improved assays and methods for allergen detection
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017096031A1 (en) 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
WO2017117236A1 (en) * 2015-12-31 2017-07-06 Siemens Healthcare Diagnostics Inc. Non-recombinant human insulin-like growth factor binding protein concentrate
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
IL265665B2 (en) 2016-10-07 2024-07-01 Regeneron Pharma A stable protein at room temperature that has been lyophilized
CN114917185B (zh) 2016-10-21 2023-11-14 美国安进公司 药物配制品及其制备方法
AU2021364523A1 (en) * 2020-10-19 2023-04-06 Oak Hill Bio Limited Compositions suitable for use in neonates
WO2023139250A1 (en) * 2022-01-24 2023-07-27 Oak Hill Bio Limited Lot release assays for igf‐1/igfbp complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
CA2172158A1 (en) 1993-09-20 1995-03-30 Joseph A. Carlino Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf
EP0729361A4 (en) 1993-11-15 1996-11-06 Celtrix Pharma METHOD FOR TREATING NEUROLOGICAL DISEASES
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
US5861273A (en) 1993-12-21 1999-01-19 Celtrix Phamraceuticals, Inc. Chromosomal expression of heterologous genes in bacterial cells
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition

Also Published As

Publication number Publication date
BR9910863A (pt) 2002-06-11
DE69918690D1 (de) 2004-08-19
WO1999062536A3 (en) 2000-03-30
US20020004478A1 (en) 2002-01-10
ATE270898T1 (de) 2004-07-15
CN1201816C (zh) 2005-05-18
WO1999062536A2 (en) 1999-12-09
AU4326799A (en) 1999-12-20
JP2002516871A (ja) 2002-06-11
EP1082133A2 (en) 2001-03-14
KR20010052500A (ko) 2001-06-25
DE69918690T2 (de) 2005-08-18
CA2330925C (en) 2010-02-09
ES2221456T3 (es) 2004-12-16
CA2330925A1 (en) 1999-12-09
CN1315868A (zh) 2001-10-03
US6436897B2 (en) 2002-08-20
US20030087806A1 (en) 2003-05-08
HK1040637B (zh) 2006-01-06
EP1082133B1 (en) 2004-07-14
HK1040637A1 (en) 2002-06-21

Similar Documents

Publication Publication Date Title
IL139969A0 (en) A pharmaceutical formulation for insulin-like growth factor and insulin like growth factor binding protein
CA2356257A1 (en) Insulin-like growth factor (igf) i mutant variants
DK0918536T3 (da) Præparat, som omfatter insulin og insulinlignende vækstfaktor-I (IGF-I)
HUP9902476A3 (en) A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent
HK1098963A1 (en) Preparations stabilized over long time
AU610636B2 (en) Stabilised human protein preparations
TW397687B (en) Stable freeze-dried formulation comprising a protein; assay kit
WO1998040401A3 (en) Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
WO1998045427A3 (en) Insulin-like growth factor agonist peptides
AU5956398A (en) Remedies for lymphocytic tumors
GB9803448D0 (en) Pharmaceutical formulation
HUP0202189A2 (en) Growth hormone formulations, method for their preparation and device and kit comprising thereof
GR3034309T3 (en) IFN--g(b) LIQUID FORMULATIONS
EP0855181A3 (en) Medicament or nutritional formulation for immune-modulation with amino acids
AU3473999A (en) Injectable igf-formulations containing succinate as buffering agent
WO1994016723A3 (en) Wound healing composition
AU1967288A (en) Growth hormone related peptide
CA2168570A1 (en) Use of growth hormone for increasement of concentration of gh, igf-i and igfbp-3 in cerebrospinal fluid
IL129442A0 (en) Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood
AUPM375994A0 (en) Stabilised growth hormone formulation
GB9918902D0 (en) Growth hormone formulation
CA2315241A1 (en) Protein rim2
MX9707088A (es) Compuestos y composiciones para suministrar agentes activos.
IL145915A0 (en) Compounds useful in reducing the levels of insulin like growth factor-1 (igf-1) in blood
AU2900989A (en) Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)